Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases

Nephrology Dialysis Transplantation

Volumn 23, Issue 11, 2008, Pages 3386-3388

  De Winter, Brenda C M ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Auto immune disease; Lupus; Mycophenolic acid; Therapeutic drug monitoring

Indexed keywords

CREATININE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANCA ASSOCIATED VASCULITIS; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; KIDNEY PERFUSION; LUPUS ERYTHEMATOSUS NEPHRITIS; NOTE; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBIOTICS, ANTINEOPLASTIC; AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; VASCULITIS;

EID: 54149100767     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn497     Document Type: Note

References (28)

1. Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-1131
2. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-236
3. Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237-243
4. Budde K, Bauer S, Hambach P et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7: 888-898
5. Stassen PM, Kallenberg CG, Stegeman CA. Use of mycophenolic acid in non-transplant renal diseases. Nephrol Dial Transplant 2007; 22: 1013-1019
6. Smak Gregoor PJ, van Gelder T, Weimar W. Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine. Neth J Med 2000; 57: 233-246
7. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005; 80(2 Suppl): S265-S271
8. McCune WJ. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005; 353: 2282-2284
9. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942
10. Sinclair A, Appel G, Dooley MA et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007; 16: 972-980
11. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66: 798-802
12. Kokolina E, Alexopoulos E, Dimitriadis C et al. Immunosuppressive therapy and clinical evolution in forty-nine patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis. Ann N Y Acad Sci 2005; 1051: 597-605
13. Hu W, Liu C, Xie H et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23: 1307-1312
14. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
15. Bennett WM. Immunosuppression with mycophenolic acid: one size does not fit all. J Am Soc Nephrol 2003; 14: 2414-2416
16. van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant 2005; 5: 199-200
17. West-Thielke P, Kaplan B. Therapeutic monitoring of mycophenolic acid: is there clinical utility? Am J Transplant 2007; 7: 2441-2442
18. De Winter BCM, Mathôt RAA, van Hest RM et al. Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome? Expert Opin Drug Metab Toxicol 2007; 3: 251-261
19. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008; 85: 1675-1685
20. van Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145-154
21. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-2503
22. Neumann I, Haidinger M, Jäger H et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003; 14: 721-727
23. Borrows R, Chusney G, James A et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit 2005; 27: 442-450
24. van Hest RM, Mathot RA, Pescovitz MD et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17: 871-880
25. van Hest RM, van Gelder T, Vulto AG et al. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005; 44: 1083-1096
26. Neumann I, Haidinger M, Jäger H et al. Association between mycophenolic acid 12-hour trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. doi:10.1093/ndt/gfn360 [epub ahead of print]
27. Pawinski T, Hale M, Korecka M et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497-1504
28. Zahr N, Amoura Z, Debord J et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet 2008; 47: 277-284